vs
Pacira BioSciences, Inc.（PCRX）とPOWER SOLUTIONS INTERNATIONAL, INC.（PSIX）の財務データ比較。上の社名をクリックして会社を切り替えられます
POWER SOLUTIONS INTERNATIONAL, INC.の直近四半期売上が大きい（$191.2M vs $177.4M、Pacira BioSciences, Inc.の約1.1倍）。POWER SOLUTIONS INTERNATIONAL, INC.の純利益率が高く（8.4% vs 1.6%、差は6.8%）。POWER SOLUTIONS INTERNATIONAL, INC.の前年同期比売上増加率が高い（32.5% vs 5.0%）。過去8四半期でPOWER SOLUTIONS INTERNATIONAL, INC.の売上複合成長率が高い（41.7% vs -0.2%）
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
アダニ・エナジー・ソリューションズ株式会社（旧称：アダニ送電株式会社）は電力の送配電事業を営む企業で、本社はアフマダーバードに所在します。2025年4月時点で累計26,696回路キロメートルの送電網を運用しており、インド最大級の民間部門送電会社の1つです。
PCRX vs PSIX — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $177.4M | $191.2M |
| 純利益 | $2.9M | $16.1M |
| 粗利率 | — | 21.9% |
| 営業利益率 | 3.9% | 12.7% |
| 純利益率 | 1.6% | 8.4% |
| 売上前年比 | 5.0% | 32.5% |
| 純利益前年比 | — | -31.0% |
| EPS（希薄化後） | $0.07 | $0.69 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $191.2M | ||
| Q3 25 | $179.5M | $203.8M | ||
| Q2 25 | $181.1M | $191.9M | ||
| Q1 25 | $168.9M | $135.4M | ||
| Q4 24 | $187.3M | $144.3M | ||
| Q3 24 | $168.6M | $125.8M | ||
| Q2 24 | $178.0M | $110.6M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $16.1M | ||
| Q3 25 | $5.4M | $27.6M | ||
| Q2 25 | $-4.8M | $51.2M | ||
| Q1 25 | $4.8M | $19.1M | ||
| Q4 24 | — | $23.3M | ||
| Q3 24 | $-143.5M | $17.3M | ||
| Q2 24 | $18.9M | $21.5M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 21.9% | ||
| Q3 25 | 80.9% | 23.9% | ||
| Q2 25 | 77.4% | 28.2% | ||
| Q1 25 | 79.7% | 29.7% | ||
| Q4 24 | 78.7% | 29.9% | ||
| Q3 24 | 76.9% | 28.9% | ||
| Q2 24 | 75.1% | 31.8% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 12.7% | ||
| Q3 25 | 3.5% | 13.9% | ||
| Q2 25 | 4.7% | 16.9% | ||
| Q1 25 | 1.2% | 18.2% | ||
| Q4 24 | 13.2% | 17.5% | ||
| Q3 24 | -82.8% | 16.3% | ||
| Q2 24 | 15.9% | 22.9% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 8.4% | ||
| Q3 25 | 3.0% | 13.5% | ||
| Q2 25 | -2.7% | 26.7% | ||
| Q1 25 | 2.8% | 14.1% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | -85.1% | 13.8% | ||
| Q2 24 | 10.6% | 19.5% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.69 | ||
| Q3 25 | $0.12 | $1.20 | ||
| Q2 25 | $-0.11 | $2.22 | ||
| Q1 25 | $0.10 | $0.83 | ||
| Q4 24 | $0.38 | $1.01 | ||
| Q3 24 | $-3.11 | $0.75 | ||
| Q2 24 | $0.39 | $0.94 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $144.3M | $41.3M |
| 総負債低いほど良い | — | $96.6M |
| 株主資本純資産 | $653.9M | $178.6M |
| 総資産 | $1.2B | $424.7M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.54× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $41.3M | ||
| Q3 25 | $246.3M | $49.0M | ||
| Q2 25 | $445.9M | $49.5M | ||
| Q1 25 | $493.6M | $50.0M | ||
| Q4 24 | $484.6M | $55.3M | ||
| Q3 24 | $453.8M | $40.5M | ||
| Q2 24 | $404.2M | $28.8M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $96.6M | ||
| Q3 25 | $376.7M | $96.7M | ||
| Q2 25 | $580.5M | $1.8M | ||
| Q1 25 | $583.4M | $1.0M | ||
| Q4 24 | $585.3M | $184.0K | ||
| Q3 24 | — | $238.0K | ||
| Q2 24 | — | $292.0K |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $178.6M | ||
| Q3 25 | $727.2M | $162.5M | ||
| Q2 25 | $757.8M | $135.7M | ||
| Q1 25 | $798.5M | $84.3M | ||
| Q4 24 | $778.3M | $65.3M | ||
| Q3 24 | $749.6M | $42.1M | ||
| Q2 24 | $879.3M | $24.8M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $424.7M | ||
| Q3 25 | $1.3B | $458.9M | ||
| Q2 25 | $1.5B | $437.7M | ||
| Q1 25 | $1.6B | $372.7M | ||
| Q4 24 | $1.6B | $328.2M | ||
| Q3 24 | $1.5B | $339.1M | ||
| Q2 24 | $1.6B | $307.6M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.54× | ||
| Q3 25 | 0.52× | 0.60× | ||
| Q2 25 | 0.77× | 0.01× | ||
| Q1 25 | 0.73× | 0.01× | ||
| Q4 24 | 0.75× | 0.00× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.01× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | — | $-4.6M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $-7.6M |
| FCFマージンFCF / 売上 | — | -4.0% |
| 設備投資強度設備投資 / 売上 | — | 1.6% |
| キャッシュ転換率営業CF / 純利益 | — | -0.29× |
| 直近12ヶ月FCF直近4四半期 | — | $14.1M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-4.6M | ||
| Q3 25 | $60.8M | $3.3M | ||
| Q2 25 | $12.0M | $16.7M | ||
| Q1 25 | $35.5M | $8.8M | ||
| Q4 24 | $33.1M | $32.7M | ||
| Q3 24 | $53.9M | $12.6M | ||
| Q2 24 | $53.2M | $1.5M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-7.6M | ||
| Q3 25 | $57.0M | $1.7M | ||
| Q2 25 | $9.3M | $14.6M | ||
| Q1 25 | $26.9M | $5.4M | ||
| Q4 24 | $31.0M | $30.0M | ||
| Q3 24 | $49.8M | $12.1M | ||
| Q2 24 | $51.6M | $822.0K |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -4.0% | ||
| Q3 25 | 31.7% | 0.8% | ||
| Q2 25 | 5.1% | 7.6% | ||
| Q1 25 | 15.9% | 4.0% | ||
| Q4 24 | 16.6% | 20.8% | ||
| Q3 24 | 29.6% | 9.7% | ||
| Q2 24 | 29.0% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.6% | ||
| Q3 25 | 2.2% | 0.8% | ||
| Q2 25 | 1.5% | 1.1% | ||
| Q1 25 | 5.1% | 2.5% | ||
| Q4 24 | 1.1% | 1.8% | ||
| Q3 24 | 2.4% | 0.3% | ||
| Q2 24 | 0.9% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | -0.29× | ||
| Q3 25 | 11.20× | 0.12× | ||
| Q2 25 | — | 0.33× | ||
| Q1 25 | 7.37× | 0.46× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 0.73× | ||
| Q2 24 | 2.82× | 0.07× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PSIX
| Energy End Market | $153.4M | 80% |
| Industrial End Market | $33.3M | 17% |
| Transportation End Market | $4.6M | 2% |
